Text
====

We report a 58-year-old man with diffuse pulmonary parenchymal plasma cell infiltration and skin nodules. Five years previously he had been treated successfully with VAD (vincristine, adriamycin and dexamethasone) chemotherapy and an autologous peripheral blood stem cell transplant for multiple myeloma. Four years later he relapsed with anemia, hypercalcemia, and an IgG of 6170 mg/dl. Skeletal survey showed no lytic lesions, the marrow was 30% infiltrated by plasma cells with a t(11;14)(q13;q32) and a del 13q14.3 abnormality. The paraprotein level transiently responded to thalidomide-dexamethasone, but he in turn developed hyperammonemia, which responded to the addition of bortezomib and liposomal pegylated doxorubicin to the regimen.

During the 3^rd^cycle of this regimen, subcutaneous nodules appeared on all four extremities, and a needle aspirate revealed plasma cells (figure [1A, B](#F1){ref-type="fig"}). The WBC rose to \> 40,000/cmm with 50% circulating plasma cells. He developed dyspnea and cough, and CT revealed peri-bronchial thickening and patchy opacities diffusely (figure [1C](#F1){ref-type="fig"}). Bronchoalveolar lavage (BAL) demonstrated kappa restricted plasma cells (Figure [1D, E](#F1){ref-type="fig"}). He soon after expired, concurrent with a rise in the ammonia level.

![**(A) Skin nodules; (B) Wright Giemsa stain, aspirate of skin nodules; (C) Chest CT showing diffuse infiltrates; (D) H&E of BAL; (E) Kappa staining of BAL**.](1756-8722-2-48-1){#F1}

Discussion
==========

In plasma cell neoplasms, pulmonary complications are common, but infection is the most common cause. In a series of 958 patients with myeloma, 10% had pulmonary findings, but in only 1 case was plasma cell involvement demonstrated histologically, and the clinical course was suggestive of plasma cell involvement in only 3 other cases \[[@B1]\]. In the literature, there are additional cases of pulmonary involvement: some of these had advanced or treatment-refractory disease, like our patient \[[@B2]-[@B4]\], whereas in several cases, the lung was the initial site of presentation \[[@B5]-[@B8]\]. Likewise, skin involvement is rare, but this too has been reported \[[@B9],[@B10]\]. We believe that this is the first case patient reported to have both sites of involvement as a complication of relapsed disease after autologous stem cell transplantation. The presence of circulating plasma cells and hyperammonemia are both known to be indicators of advanced disease. Plasma cell neoplasm should be kept in the differential diagnosis of any pulmonary infiltrate not responding to antibiotics or as a possible cause of skin nodules in a patient with a history of myeloma, plasmacytoma, or MGUS.
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